CARDIOGENICS HOLDINGS INC Inactive Instrument
CardioGenics Holdings Inc Stock Other OTC
Equities
CGNH
US14160X2036
Medical Equipment, Supplies & Distribution
| Sales 2014 | - | Sales 2015 | - | Capitalization | 4.61M 6.3M |
|---|---|---|---|---|---|
| Net income 2014 | -2M -2.73M | Net income 2015 | -1M -1.37M | EV / Sales 2014 | - |
| Net Debt 2014 | 132K 181K | Net Debt 2015 | 157K 214K | EV / Sales 2015 | - |
| P/E ratio 2014 |
-2.3
x | P/E ratio 2015 |
-2.17
x | Employees | - |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 97.49% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Yahia A. Gawad
FOU | Founder | 66 | 97-11-19 |
James A. Essex
DFI | Director of Finance/CFO | 76 | 98-12-31 |
| Director/Board Member | 63 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 02-12-31 | |
Yahia A. Gawad
FOU | Founder | 66 | 97-11-19 |
| Director/Board Member | 63 | 00-12-31 |
CardioGenics Holdings Inc. is focused on technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. The Company has developed the QL Care Analyzer, a point-of-care immuno-analyzer, which is capable of running approximately 200+immunoassay diagnostic tests, such as cardiovascular diagnostic tests. As part of its technology, the Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improves instrument sensitivity to light.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
